Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
暂无分享，去创建一个
M. Kudo | A. Santoro | A. El-Khoueiry | B. Sangro | T. Yau | Chiun Hsu | Tae-You Kim | Yoon-Koo Kang | J. Neely | I. Melero | J. Knox | F. Tovoli | B. El-Rayes | M. Tschaika | A. He | A. Matilla | Yun Shen | M. Hou | M. Acosta-Rivera